| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 01/15/2003 | CN1390545A Prescription and preparing process of dispamil injection |
| 01/15/2003 | CN1390542A Freeze-dried ginkgolide powder injection and its preparing process |
| 01/15/2003 | CN1098849C 噻唑衍生物 Thiazole derivatives |
| 01/15/2003 | CN1098848C Acids and esters of diosmetin and pharmaceutical compositions containing them |
| 01/15/2003 | CN1098706C Medicine for curing coronary heart disease |
| 01/15/2003 | CN1098704C Preparation of hemiplegia treating capsule |
| 01/15/2003 | CN1098702C Chinese medicine for lowering blood pressure |
| 01/15/2003 | CN1098701C Medicine for cardio-cerebral angiopathy |
| 01/15/2003 | CN1098700C Chinese patent medicine for treating piles |
| 01/15/2003 | CN1098682C Pharmaceutical process of crocus sativus polyglycoside and its tablets |
| 01/14/2003 | US6506937 Used as antiarrhythmics |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506879 Endotoxin-free; genetically expressed in bacteria; atherosclerosis and cardiovascular disorder treatment |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506799 Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and |
| 01/14/2003 | US6506797 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) α |
| 01/14/2003 | US6506781 Prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506774 The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. |
| 01/14/2003 | US6506772 Pharmaceutically active salts thereof with activity as adenosine receptor ligands are disclosed. These compounds are the adenosine receptor. |
| 01/14/2003 | US6506768 Tetrahydro γ-carbolines |
| 01/14/2003 | US6506762 Certain alkylene diamine-substituted heterocycles |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506750 Morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/14/2003 | US6506745 Medical composition for atrial fibrillation treatment, comprising a compound with benzene and benzothiazole compounds |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506731 Elastin peptide analogs and methods of using same |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506408 Implantable or insertable therapeutic agent delivery device |
| 01/14/2003 | CA2114313C Bpc peptides, their preparation and use |
| 01/14/2003 | CA2023089C Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia |
| 01/09/2003 | WO2003003018A2 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/09/2003 | WO2003003017A2 Use of transcription factor nak-1 or genes regulated by transcription factor nak-1 for the diagnosis and/or therapy of inflammatory and malignant diseases |
| 01/09/2003 | WO2003003011A1 Modification of angiogenesis by targeting protein tyrosine phosphatases |
| 01/09/2003 | WO2003002755A2 Glaucoma treatments with reduced hyperpigmentation |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002586A1 [4-(4-cyanobenzoyl)phenyl]glycofuranoside derivatives, use of said derivatives as a medicament, production method thereof and pharmaceutical compositions containing same |
| 01/09/2003 | WO2003002585A1 [4-(4-cyanobenzoyl)phenyl]glycopyranoside derivatives, use of same as a medicament, production method thereof and compositions |
| 01/09/2003 | WO2003002575A1 3-ARYL-$G(a)-OXY SUBSTITUTED PROPANOIC ACIDS AND A PROCESS FOR THEIR PREPARATION |
| 01/09/2003 | WO2003002568A1 Carbohydrate derivatives |
| 01/09/2003 | WO2003002566A1 Purine derivatives as a2b adenosine receptor antagonists |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002559A2 Piperidine compounds for use as orexin receptor antagonist |
| 01/09/2003 | WO2003002556A1 Novel heteroaryl derivatives, their preparation and use |
| 01/09/2003 | WO2003002555A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/09/2003 | WO2003002554A1 Piperazine compounds |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002540A1 Cyclic diamine compound having five-membered cyclic group |
| 01/09/2003 | WO2003002537A1 Bis(5-aryl-2-pyridyl) derivative |
| 01/09/2003 | WO2003002535A1 Cyclic diamine compounds bearing six-membered cyclic groups |
| 01/09/2003 | WO2003002533A1 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| 01/09/2003 | WO2003002532A1 Cyclic diamine compounds having fused-ring groups |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002524A2 Urea derivatives with antiproteolytic activity |
| 01/09/2003 | WO2003002158A1 The use of angiotensin i derivative as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| 01/09/2003 | WO2003002147A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 01/09/2003 | WO2003002146A1 Medicinal compositions |
| 01/09/2003 | WO2003002144A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002127A1 Use of at least one glycoinhibitor substance |
| 01/09/2003 | WO2003002124A1 USE OF BIS-ACID(5-ANDROSTEN-17-ONE-3β-HYDROXYL) DIESTERS FOR MANUFACTURE PHARMACEUTICALS |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002119A1 Treatment and prevention of lipodermatosclerosis |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002109A2 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | WO2003002106A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2003002044A2 Method of inhibiting the proliferation of vascular smooth muscle cells |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002076376A3 A stable pharmaceutical composition of pravastatin |
| 01/09/2003 | WO2002072536A8 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 01/09/2003 | WO2002071874A3 Composition improving age-related physiological deficits and increasing longevity |
| 01/09/2003 | WO2002064594A3 6-substituted pyrido-pyrimidines |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002046373A9 Method of collecting placental stem cells |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002042437A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |
| 01/09/2003 | WO2002015845A3 Anti-hypercholesterolemic drug combination |
| 01/09/2003 | WO2002003970A2 Matrix controlled transdermal system for stabile derivatives of ace inhibitors |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001097793A3 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 01/09/2003 | WO2001090390A9 Use of baculovirus vectors in gene therapy |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001056532A9 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |